Baker BROS. Advisors LP Invests $25.32 Million in Jade Biosciences, Inc. $JBIO

Baker BROS. Advisors LP bought a new position in Jade Biosciences, Inc. (NASDAQ:JBIO) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,641,137 shares of the company’s stock, valued at approximately $25,323,000. Baker BROS. Advisors LP owned 3.33% of Jade Biosciences at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JBIO. JPMorgan Chase & Co. purchased a new position in shares of Jade Biosciences in the 2nd quarter worth $154,000. Legal & General Group Plc purchased a new position in shares of Jade Biosciences in the 2nd quarter worth $29,000. Rhumbline Advisers purchased a new position in shares of Jade Biosciences in the 2nd quarter worth $445,000. Russell Investments Group Ltd. purchased a new position in shares of Jade Biosciences in the 2nd quarter worth $31,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Jade Biosciences in the 2nd quarter worth $114,000.

Analyst Ratings Changes

Several research analysts recently weighed in on JBIO shares. HC Wainwright increased their target price on Jade Biosciences from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. BTIG Research increased their target price on Jade Biosciences from $39.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Wall Street Zen lowered Jade Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. William Blair raised Jade Biosciences to a “strong-buy” rating in a research report on Monday, March 9th. Finally, Wedbush increased their target price on Jade Biosciences from $34.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.13.

Jade Biosciences Stock Up 8.6%

Shares of JBIO stock opened at $16.87 on Thursday. The business has a 50 day moving average of $21.01 and a two-hundred day moving average of $16.88. Jade Biosciences, Inc. has a 52 week low of $6.67 and a 52 week high of $28.00. The company has a market cap of $832.70 million, a P/E ratio of -8.35 and a beta of 1.44.

Jade Biosciences (NASDAQ:JBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). Analysts expect that Jade Biosciences, Inc. will post -2.54 EPS for the current fiscal year.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.